Advertisement
Canada markets close in 3 hours 40 minutes

  • S&P/TSX

    21,982.65
    +97.27 (+0.44%)
     

  • S&P 500

    5,102.18
    +53.76 (+1.06%)
     

  • DOW

    38,247.31
    +161.51 (+0.42%)
     

  • CAD/USD

    0.7312
    -0.0011 (-0.15%)
     

  • CRUDE OIL

    84.07
    +0.50 (+0.60%)
     

  • Bitcoin CAD

    86,861.08
    -667.16 (-0.76%)
     

  • CMC Crypto 200

    1,322.53
    -74.01 (-5.30%)
     

  • GOLD FUTURES

    2,348.40
    +5.90 (+0.25%)
     

  • RUSSELL 2000

    1,998.05
    +16.93 (+0.85%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • NASDAQ

    15,926.87
    +315.11 (+2.02%)
     

  • VOLATILITY

    15.30
    -0.07 (-0.46%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Portnoy Law: Lawsuit Filed On Behalf of AcelRx Pharmaceuticals, Inc. Investors

Portnoy Law
·1 min read

Click here to join the case

LOS ANGELES, June 15, 2021 (GLOBE NEWSWIRE) --
​
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the Company") (NASDAQ: ACRX) investors that acquired securities between March 17, 2020 and February 12, 2021.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading and false statements and/or failed to disclose that: (1) AcelRx’s disclosure controls and procedures with respect to its marketing of DSUVIA were deficient; (2) AcelRx had been making misleading or false claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, as a result; (3) the foregoing conduct subjected AcelRx to increased regulatory enforcement and scrutiny; and (4) AcelRx’s public statements were materially false and misleading at all relevant times, as a result.

ADVERTISEMENT

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising